Stock Comparison

PPBT vs UNH

Purple Biotech Ltd vs UnitedHealth Group Inc

The Verdict

PPBT takes this one.

Winner

PPBT

Purple Biotech Ltd

6.6

out of 10

Solid Pick

UNH

UnitedHealth Group Inc

0.3

out of 10

Distressed

Head-to-Head

$6M

Market Cap

$276.2B

0.0

P/E Ratio

22.9

0.0%

Profit Margin

2.7%

-12.4%

Return on Equity

12.5%

0.0

Debt-to-Equity

0.0

Aggressive

Overall Risk

Moderate-High

6.6

DVR Score

0.3

The Deep Dive

PPBT6.6/10

Purple Biotech targets high-unmet-need oncology markets with a promising diversified pipeline, including the novel CAPTN-3 tri-specific antibody platform progressing towards IND (Q4 2026) and two Phase 2 assets (CM24, NT219) positioned for partnerships, indicating substantial TAM and significant 10x potential upon clinical success. A crucial positive development since the last analysis is the exte...

Full PPBT Analysis

UNH0.3/10

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...

Full UNH Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.